SCHEDULE
14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by
the Registrant o
Filed by a
Party other than the Registrant x
Check the appropriate box:
| o | Preliminary Proxy Statement | |
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| o | Definitive Proxy Statement | |
| o | Definitive Additional Materials | |
| x | Soliciting Material Pursuant to Section 240.14a-12 |
ANIMAS CORPORATION
(Name of Registrant as Specified in Its Charter)
JOHNSON & JOHNSON
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| x | No fee required. | |
| o | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: | ||
| (2) | Aggregate number of securities to which transaction applies: | ||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | ||
| (4) | Proposed maximum aggregate value of transaction: | ||
| (5) | Total fee paid: | ||
| o | Fee paid previously with preliminary materials. | |
| o | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: | ||
| (2) | Form, Schedule or Registration Statement No.: | ||
| (3) | Filing Party: | ||
| (4) | Date Filed: | ||
On December 16, 2005, Johnson & Johnson and one of its affiliates each delivered presentations to employees of Animas Corporation. A copy of each presentation is included below.
*****************
| Founded 1886 New Brunswick, New Jersey In a Former Wallpaper Factory By three brothers with a dream... that Joseph Lister's theories about sterilization could save lives in America's hospitals |
| World's Most Comprehensive and Broadly Based Health Care Company |
| 200+ Operating Companies In 57 Countries Around the World Selling Products in More Than 175 Countries Global Presence |
| 115,000 Employees Worldwide Global Presence |
| Strategic Principles Broadly based in Human Health Care Decentralized Management Manage for the Long Term Ethical Principles Our Credo |
| Our Credo Written by General Robert Wood Johnson, Jr. in the 1940s Visionary and U.S. business leader Among the first to speak openly of a company's responsibility |
| Our Credo The Four Tenets Customers Employees Community Shareholders Shareholders Shareholders Shareholders Shareholders Shareholders |
| 13.1% 18.3% 18.2% Sales Diluted EPS Net Earnings $47.3B $8.5B $2.84 2004 Performance Results |
| Consumer Pharmaceutical MD&D East 0.18 0.47 0.36 Medical Devices & Diagnostics $16.9 B Pharmaceuticals $22.1 B $ U.S. Billions 46.7% 17.6% 35.7% 2004 Sales by Segment Consumer $8.3 B Total Sales: $47.3 Billion |
| 2004 Sales by Geographic Area Asia, Pacific, Africa U.S. Europe W. Hemisphere 0.123 0.59 0.234 0.055 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 23% 59% 6% Europe $11.1 Billion U.S. $27.8 Billion W. Hemisphere $2.6 Billion Asia, Pacific, Africa $5.8 Billion 12% Total Sales: $47.3 Billion |
| Historical Performance 100 +10.6% +11.0% +10.7% 50 +11.1 +11.7 +14.2 20 +10.9 +10.8 +15.6 10 +11.8 +12.3 +16.9 5 +11.6 +11.1 +16.9 1 +13.1 +9.7 +16.8 Net Income(1) Reported Sales Operational Sales Year (1) Proforma excluding In-process R&D, taxes on repatriated cash under the AJC Act and other charges and credits |
| Historical Performance 72 Consecutive years of Sales increases 20 Consecutive years of double digit Earnings increases(1) 42 Consecutive years of Dividend increases (1) Proforma excluding In-process R&D, taxes on repatriated cash under the AJC Act and other charges and credits |
| Investment in Research 1994 1995 1999 2004 R&D Expense Total J&J 0.5 1.8 2.1 2.4 2.5 2.8 3.1 3.6 4 4.7 5.2 Pharm 0.9 1.1 1.3 1.5 1.6 1.8 2.2 2.5 2.7 3.2 3.6 North 45.9 46.9 45 43.9 9.6% Percent to Sales 11.0% $U.S. Billions |
| Products Patients & Customers |
| LifeScan: The Road Ahead Eric Milledge Company Group Chairman |
| LifeScan Vision "Creating a world without limits for people with diabetes" |
| LifeScan Around the World U.S./Puerto Rico: 1290 Canada: 118 EMEA: 667 Scotland: 478 Employees by region: |
| Worldwide Glucose Monitoring Market 2003 2004E 2006E 2009E 2011E U.S. 2.2 2.4 2.6 3.3 4 EX U.S. 2.9 3.3 3.9 5 6 $ Billions Ex U.S. U.S. CAGR 8% 5.1 5.7 6.5 8.3 10 .0 Source: LifeScan Estimates, Analyst Reports |
| LifeScan Dollar Sales |
| LifeScan Key Products Source: International Diabetes Federation |
| LifeScan Mission "To fundamentally change our business from measurement to management, and transform LifeScan from an episodic monitoring company to a true diabetes management company." |
| Our Strategic Direction Continued leadership in Glucose Monitoring Expansion into Insulin Delivery Creation of Diabetes Management solutions Episodic Continuous Diabetes Management Glucose Monitoring Medication Insulin Delivery |
| Culture For Success Extraordinary talent Entrepreneurship - intelligent risk taking Collaboration and team work Passion and sense of urgency Speed, flexibility, and agility Flawless execution |
| Our Credo |
| Critical To Success Voice of Customer Design Excellence Clinical & Economic Outcomes Quality & Compliance Intellectual Property Organization & People Development |